Amylin Pharmaceuticals News

Amylin Pharmaceuticals Inc. , the diabetes drugmaker that's up for sale, has received first-round bids from Sanofi and Merck & Co.

GlaxoSmithKline Plc will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc., its partner on the drug.

Very few sectors have been able to avoid the sell-off in May. The strongest of the group has been the biotech stocks, which measured by the Dow Jones Biotechnology Index, is at an all-time high.

Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs.

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF where we have detected an approximate $91.0 million dollar inflow - that's a 16.7% increase week over week in outstanding units .

As leaders in Athens accepted the need for a new general election to end a national stalemate, the International Monetary Fund said Europe's leaders should prepare for the possibility of a Greek departure from the single currency.

As Wall Street continues to chew on the developing political drama in Greece, stocks are wavering around breakeven this afternoon .

Top Stories German recovery helps eurozone avoid recession. German GDP rebounded in Q1 to rise 0.5% on quarter, more than double forecasts of +0.2%, boosted by exports to emerging markets.

Amylin Pharmaceuticals Inc. has lured suitors such as Pfizer Inc. , AstraZeneca Plc and Sanofi, which signed confidentiality agreements on the drugmaker's sale process, said people familiar with the matter.

May 08, 2012 -- Marcea Bland Lloyd, Senior Vice President, Chief Administrative Officer and General Counsel at San Diego-based Amylin Pharmaceuticals, was recently honored by Athena San Diego as she received the 2012 Pinnacle Award for the "Individual in Life Science" category.

CLARK, N.J. and SAN DIEGO, May 8, 2012 /PRNewswire/ -- HealthEd announced seasoned biopharma executive Vicki Kelemen has joined as Senior Vice President and will lead the company's growing business on the West Coast.

AstraZeneca has been backed in to a corner, but it looks as though the drug maker is ready to come out swinging.

Biotech companies are fighting back against Big Pharma and the little guys are surprisingly effective.

Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering the following companies: Report Summary for: AmerisourceBergen Corp.

What gives? Let's look at the sales numbers for the last few quarters to see whether we can parse it out.

's stock had its "neutral" rating reiterated by Zacks in a research note issued to investors on Monday.